GEBRO, Spektus Pharma Partner on ActraFlex
The two companies signed a global commercialisation agreement for the twice-daily extended-release pain therapy ActraFlex.
Updated on Nov. 4, 2026 in Arthritis
GEBRO Holding and Spektus Pharma signed a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice a day. The financial terms of the deal were not disclosed.
Why it matters
The agreement divides commercial responsibility for the product by region, with GEBRO covering Europe and selected global markets and Spektus covering Africa, the Americas, and Asia. Each company will manage regulatory approval and commercial operations within its own territories.
ActraFlex is dosed twice a day and combines paracetamol and tramadol in a sustained-release formulation. The companies have not disclosed deal financials, and regulatory timelines in each territory remain unspecified.
The players
GEBRO Holding
GEBRO Holding is an Austrian pharmaceutical company with experience in developing and commercialising specialised medicines, with a particular focus on rheumatoid arthritis and pain management.
Spektus Pharma
Spektus Pharma is a Canadian pharmaceutical company that owns the AmyloFlex drug-delivery technology integrated into ActraFlex.
The details
ActraFlex integrates Spektus' AmyloFlex drug-delivery technology with GEBRO's Diliban product, which already has an established commercial presence in Spain. GEBRO will anchor supply and commercialisation across Europe from Spain, while Spektus will rely on regional pharmaceutical partners in its territories.
Timeline
4 November 2026: Announcement of the GEBRO and Spektus commercialisation agreement for ActraFlex.
Big Picture
The partnership extends Spektus Pharma's proprietary AmyloFlex drug-delivery technology into a combined product with GEBRO's Diliban, shifting the platform from development toward commercial distribution across multiple regions.
ActraFlex is taken twice a day, so patients on the therapy would follow a twice-daily dosing schedule. Availability will depend on each territory's regulatory approval, which the companies will manage separately within their assigned regions.
The takeaway
Regional split commercialisation is a common structure for specialised medicines, and patients and clinicians should check local regulatory status before expecting ActraFlex to be available in their country. Official approval timelines will determine when the product reaches each market.
Further reading
For background on the condition GEBRO focuses on, see Arthritis.
